Management reaffirmed its guidance for reporting top-line data for the PIK3CA wild-type cohort in Q2 2025 and the mutant cohort in Q4 2025. The VIKTORIA-2 Phase III trial remains on track to enroll ...
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc (ORGS). (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and ...
NEW YORK, Oct. 14, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced that the 2025 Inaugural Galien Patient ...
Patient monitoring devices consist of medical devices that monitor a patient's vital signs and symptoms, which have a significant role in healthcare settings with their capacity to improve real-time ...
CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...
The future of healthcare marketing lies at the crucial intersection of data and context. It’s no longer enough to rely on data to just know who your audience is, or even where they might be—you must ...
Vonjo shows promise in improving blood counts for myelofibrosis patients, enhancing quality of life by reducing anemia-related symptoms. Antibody-drug conjugates are increasingly used in metastatic ...
In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses how hypertargeting and contextual relevance are redefining patient marketing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback